Literature DB >> 34287847

Differences in cytokine and chemokine profiles in cerebrospinal fluid caused by the etiology of cryptococcal meningitis and tuberculous meningitis in HIV patients.

Lijun Xu1,2, Yufan Xu1,3, Yanghao Zheng1,4, Xiuming Peng5, Zongxing Yang6, Qing Cao1,2, Dairong Xiang1,2, Handan Zhao1,4.   

Abstract

The roles of cytokines and chemokines in HIV-associated cryptococcal meningitis (HCM) and HIV-associated tuberculous meningitis (HTBM) are debatable. In sum, 34 HIV-infected patients without meningitis, 44 HCM patients and 27 HTBM patients were enrolled for study. The concentrations of 22 cytokines/chemokines in cerebrospinal fluid (CSF) were assayed at admission. Principal component analysis (PCA), Pearson's and logistic regression analyses were used to assess the role of cytokines/chemokines in HCM and HTBM. We found the levels of T helper (Th)17, Th1 [interleukin (IL)-12p40, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and TNF-β and Th2 (IL-2/4/5/6/10)] cytokines were elevated in patients with meningitis compared with those in HIV-infected patients without central nervous system (CNS) infection. Furthermore, the IL-1Ra, IL-12p40, IL-17α and monocyte chemotactic protein-1 (MCP-1) levels were higher in HCM patients, while the IFN-γ, regulated upon activation, normal T cell expressed and secreted (RANTES) and interferon-inducible protein-10 (IP)-10 levels were higher in HTBM patients. Elevated CSF concentrations of IL-17a, TNF-β, IL-5, IL-12p40 and IL-1Rα were closely related to meningitis, but elevated IP-10, MCP-1, RANTES and IFN-γ levels and CSF white blood cells (WBCs) were protective factors against HCM. Our study suggested that HIV-infected patients with low CSF WBCs have a high risk of HCM. Th1, Th2 and Th17 cytokines/chemokines mediate differences in the pathogenesis of HCM and TBM. Overexpressed proinflammatory MCP-1, RANTES, IFN-γ and IP-10 in CSF are protective factors against HCM but not HTBM.
© 2021 British Society for Immunology.

Entities:  

Keywords:  zzm321990Cryptococcuszzm321990; HIV; chemokine; cytokine; meningitis

Mesh:

Substances:

Year:  2021        PMID: 34287847      PMCID: PMC8446401          DOI: 10.1111/cei.13644

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  39 in total

1.  Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis.

Authors:  Ji-Soo Kwon; Joung Ha Park; Ji Yeun Kim; Hye Hee Cha; Min-Jae Kim; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Yong Seo Koo; Sang-Beom Jeon; Sang-Ahm Lee; Sung-Han Kim
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

Review 2.  The role of CD40 ligand in costimulation and T-cell activation.

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Rev       Date:  1996-10       Impact factor: 12.988

3.  Unique clinical features of cryptococcal meningitis among Chinese patients without predisposing diseases against patients with predisposing diseases.

Authors:  Lijun Xu; Xinyue Zhang; Yongzheng Guo; Ran Tao; Xiahong Dai; Zongxing Yang; Ying Huang; Biao Zhu; Yan Xu
Journal:  Med Mycol       Date:  2019-11-01       Impact factor: 4.076

4.  Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry.

Authors:  S A Klein; J M Dobmeyer; T S Dobmeyer; M Pape; O G Ottmann; E B Helm; D Hoelzer; R Rossol
Journal:  AIDS       Date:  1997-07-15       Impact factor: 4.177

5.  Detection of HIV RNA levels in intraocular and cerebrospinal fluids in patients with AIDS-related cryptococcosis.

Authors:  Chi-Hsien Peng; Shih-Jen Chen; Chi-Kung Ho; Hung-Hai Ku; Hon-Wun Lin; Steve S-L Chen; Chih-Chiau Wu; Chin-Wen Chi; Wen-Ming Hsu; Shih-Hwa Chiou
Journal:  Ophthalmologica       Date:  2005 Mar-Apr       Impact factor: 3.250

6.  Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.

Authors:  Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2013-12-06       Impact factor: 9.079

7.  Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis.

Authors:  Joseph N Jarvis; Graeme Meintjes; Tihana Bicanic; Viviana Buffa; Louise Hogan; Stephanie Mo; Gillian Tomlinson; Pascale Kropf; Mahdad Noursadeghi; Thomas S Harrison
Journal:  PLoS Pathog       Date:  2015-04-08       Impact factor: 6.823

8.  Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis.

Authors:  Suzaan Marais; Rachel P J Lai; Katalin A Wilkinson; Graeme Meintjes; Anne O'Garra; Robert J Wilkinson
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 9.  The Role of IL-17 in Protection against Mucosal Candida Infections.

Authors:  Bemnet G Mengesha; Heather R Conti
Journal:  J Fungi (Basel)       Date:  2017-09-27

10.  Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis.

Authors:  Romain A Colas; Le Thanh Hoang Nhat; Nguyen Thuy Thuong Thuong; Esteban A Gómez; Lucy Ly; Hai Hoang Thanh; Nguyen Thi Hoang Mai; Nguyen Hoan Phu; Guy E Thwaites; Jesmond Dalli
Journal:  FASEB J       Date:  2019-10-05       Impact factor: 5.191

View more
  1 in total

1.  Differences in cytokine and chemokine profiles in cerebrospinal fluid caused by the etiology of cryptococcal meningitis and tuberculous meningitis in HIV patients.

Authors:  Lijun Xu; Yufan Xu; Yanghao Zheng; Xiuming Peng; Zongxing Yang; Qing Cao; Dairong Xiang; Handan Zhao
Journal:  Clin Exp Immunol       Date:  2021-08-08       Impact factor: 5.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.